Navigation Links
Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial
Date:10/24/2011

ROCKVILLE, Md., Oct. 24, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of its ongoing Phase I safety trial of the company's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing safety data from the first 12 patients, the Food and Drug Administration (FDA) has granted approval for the trial to advance to transplanting patients in the cervical (upper back) region. Until now, patients have received injections in the lumbar (lower back) region only.  Earlier this summer, the trial's Safety Monitoring Board unanimously approved moving to the cervical injection phase. The trial will now advance to the final two cohorts of patients with ALS, all of whom will be transplanted in the cervical region of the spine.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"The goal of our cell therapy program is to create therapies that will slow down, stabilize, or  reverse, functional deficits in central nervous system (CNS) diseases," said Karl Johe, PhD, Neuralstem Chairman and Chief Scientific Officer. "By moving the cell delivery to cervical spinal cord—the first time the FDA has approved intraspinal injections in this region—we will demonstrate that we can deliver our cells safely and routinely to all parts of the spinal cord."

The trial is under the direction of Principal Investigator, Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System, and Jonathan D. Glass, MD, Director of the Emory ALS Center. The surgeries are performed by Emory Neurosurgeon, Nicholas M. Boulis, MD. Dr. Feldman is an unpaid consultant to Neuralstem.

In a joint statement, the three do
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
2. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
3. Neuralstem Updates NSI-189 Major Depression Trial
4. Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
5. Neuralstem Updates ALS Clinical Trial Progress
6. Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
7. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
8. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
9. Neuralstems ALS Trial on Clinical Hold
10. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
11. Neuralstem Announces Issuance of Core Technology Patent in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
(Date:4/23/2014)... LAFAYETTE, Ind. - Purdue University researchers have developed a ... living cell by using tiny gold particles with tails ... professor of agricultural and biological engineering, used gold nanoparticles ... known as BRCA1 messenger RNA splice variants, which can ... number of these mRNA splice variants in a cell ...
(Date:4/23/2014)... internal surface area of the gastro-intestinal tract has long ... meters. Scientists at the Sahlgrenska Academy have used refined ... "Actually, the inner surface of the gastro-intestinal tract is ... scientist Lars Fndriks. , The digestive tract, which passes ... the intestines, has a length of about 5 meters ...
(Date:4/23/2014)... and accessible detection methods that can rapidly screen ... a single cell inside that population has been ... Lu. , In the Royal Society of Chemistry ... that he and his coworkers have developed a ... a protein ( Chem. Sci. , 2014, DOI: ...
(Date:4/23/2014)... often displayed in the popular Swedish children,s TV ... high-sugar foods. A new study from the University ... children,s TV programmes as well as the link ... weight status. , Steingerdur Olafsdottir,s doctoral thesis focuses ... Swedish children,s TV show Bolibompa. Healthy foods dominated ...
(Date:4/23/2014)... by a researcher from the Cancer Science Institute of ... has identified the cancer specific stem cell which causes ... developing new drugs for the treatment of this disease ... led by Dr Chan Shing Leng, Research Assistant Professor ... a cancer-specific variant of a cell surface protein, CD44v8-10, ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
... chemo can help avoid treatment toxicity, research shows , ... with immunodeficiencies, researchers may have found a better way ... stem-cell transplants. , A regimen using antibodies instead ... children, according to Dr. Persis J. Amrolia, a doctor ...
... TALLAHASSEE, Fla., Sept. 2 Pharmavite, a global leader in ... to test the impact of shopper education on retail purchasing of ... number of retail stores for a ninety-day trial period, LearnSomething,s ShopperAssist(TM) ... an LCD screen with ten user selectable buttons, shoppers will be ...
... , , THE WOODLANDS, Texas, Sept. 2 ... of America,s fastest-growing private companies - the Inc. 500. Inc. ... the top quarter as #117 with a three-year sales growth of 1,424%. ... are going to change the world, look at the Inc. 500," said ...
... Danaher Corporation (NYSE: DHR ) today announced that ... MDS; NYSE: MDZ ) to acquire the Analytical ... in Applied Biosystems/MDS Sciex joint venture ("AB SCIEX"), a mass ... Molecular Devices Corporation, a bioresearch and analytical instrumentation company. ...
... , , PRINCETON, N.J., ... of Ranbaxy Laboratories Limited (RLL), Gurgaon, India, announced an agreement with ... version of Rocaltrol(R) (calcitriol) in both softgel capsules and an oral ... oral liquid were $70 million (IMS - MAT: June 2009). ...
... , CINCINNATI, Sept. 2 LCA-Vision Inc. (Nasdaq: ... Lasik Plus ((R)) brand, today announced that members of its executive management ... , FTN Equity Capital Markets Corp. ... 2 at the Grand Hyatt Hotel in New York City; , ...
Cached Medicine News:Health News:New Technique Offers Hope for Kids With Immune Deficiency 2Health News:Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 2Health News:Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 3Health News:eCardio Included on Inc. Magazine's 28th Annual List of America's Fastest-Growing Private Companies -- the Inc. 500 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 3Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 4Health News:Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) 2Health News:Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) 3Health News:LCA-Vision to Present at September Investment Conferences 2
The most compact revolutionary innovation in hematology. 26 parameters with 5 Part DIFF...
... is a compact, stand-alone microprocessor-controlled photometer designed ... 96-well microplates using single- or dual- wavelength ... and a dynamic reading range up to ... any laboratory or assay requirements. Self-diagnostics (up ...
... System is made up of three integral ... and the Merci Balloon Guide Catheter. The ... location of the clot has been identified ... is inserted through a small incision in ...
A 3080/3085 orthopedic extension serves as a mobile, radiolucent orthopedic platform. When not in use, accessories can be removed and stored in cart....
Medicine Products: